about
Cerebral microbleeds in early Alzheimer's disease.[Modern trends in epidemiology of dementia and management of patients with cognitive impairment].[Neuropsychiatric disorders in dementia: mechanisms and treatment approach].[Diagnostic of prodromal dementia with Levy bodies].[Social cognitive function in neurodegenerative diseases].[Screening of cognitive impairment in the old and old-old population with the 3-CT scale].[Twenty-five years of the amyloid hypothesis of alzheimer disease: advances, failures and new perspectives].[Possibilities of retention of work capacity in patients with Parkinson's disease][Rate of progression of Parkinson's disease with early and delayed prescription of levodopa preparations.][The addition of memantine to galantamine increases treatment efficacy in patients with moderate dementia with Lewy bodies][Autoimmune anti-NMDA-R encephalitis][Characteristics of the clinical picture and treatment of moderate or severe Alzheimer's disease][Event-related potentials in Parkinson's disease][Characteristics of Parkinson's disease course in the heterozygous carriage of mutations in the glucocerebrosidase A gene][Speech disorders in Parkinson's disease][Rapidly progressive dementia][The efficacy and safety of naproxen in the treatment of nonspecific lumbalgia: the results of an open multi-center study (NEST)][Depression and cognitive decline in elderly: causes and consequences][The feasibility of using Quick Dementia Rating System in clinical practice: results of a multi-center prospective validation study][Speech disorders and anxiety: interaction mechanisms and therapy potential]
P50
Q47986923-63029F00-074E-446F-A8CE-F38927103B7AQ49585727-D3995525-BE5A-4003-B87A-46FCDF9DAA46Q49585767-88E1711C-C4FB-4819-95BB-8584D9BAF421Q49585803-34642F35-94BB-4A37-9558-22CBBC22923FQ49627195-8DC54BDD-C07C-4617-9E3E-9535436CBCC4Q50621117-DB21D800-3D0A-40CF-8BA8-891C39313575Q52675693-9EEBE307-A708-4A54-963D-4668C25B2377Q57826848-7BA4FF82-D8A8-427F-8045-2E548E947878Q57826853-5A355337-FA7F-4A5D-9AFB-42258E3EB065Q57826868-2C71617A-82A4-4F32-85F2-E4B9C0F9131FQ87747450-DF192C53-DB87-470B-BA7B-2A30D86D62D2Q88356849-E18EC0FD-AFF5-4654-B4CE-D3F4B2FF3C7CQ88356871-7CB9D2EA-0626-4A32-9E0A-3CE2132BFF6AQ88523396-158A0F09-0D82-4BF0-A6D7-262009D5D612Q91874945-ABFB0F20-96ED-410B-A61D-B453AE90F698Q91874972-01415C08-E600-4891-BB97-C0DDE6F1DCDBQ91981921-A4060D9D-9ABD-4B92-B66D-44374244E2C3Q92975284-7B908086-574D-4D73-8DBF-1801FA967DCEQ93383504-BEB7BA71-B0DB-410A-AA7E-8DA6735B0218Q96113801-68FA206E-52D8-4976-8D56-F9027C86F5DD
P50
description
researcher
@en
name
E E Vasenina
@en
type
label
E E Vasenina
@en
prefLabel
E E Vasenina
@en
P31
P496
0000-0002-2600-0573